Cara Mathews, MD, spoke with CancerNetwork® about research examining dostarlimab vs doxorubicin for patients with mismatch repair–deficient endometrial cancers.
Cara Mathews, MD
Advertisement
Articles by Cara Mathews, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Atezolizumab Combo Elicits No Significant Benefit in Ovarian Cancer
2
Glofitamab/Polatuzumab Vedotin Exhibits Response Durability in R/R LBCL
3
How Can Oncology Staffing Shortages Be Remedied?
4
Lifileucel Confers Durable Responses in Pretreated Advanced NSCLC Type
5
